“…Our preliminary radiolabeling attempts resulted in the radiolabeled 5-pyrrolidinylsulfonyl isatin derivative [ 125 I] 26 . In future studies, the synthesized precursors 7 , 8 , 17 , 18 , 23 , 24 , 31 , and 32 will be radiolabeled with different radionuclides, including iodine-123, fluorine-18, or carbon-11, which are typically used for noninvasive scintigraphic imaging using SPECT and PET. − This should result in lead candidate CBRs capable of intracellular targeting early stages of the apoptotic process. Caspase activation occurs in all settings of clinically relevant apoptosis, such as that in acute myocardial infarction, chronic heart failure, allograft rejection, stroke, neurodegenerative disorders, induction of apoptosis by chemotherapy or irradiation, and in other pathological conditions. − If successfully applied in clinical diagnostic algorithms in the future, the CBRs could represent the first synthetic nonpeptidyl biomarkers (radiotracers) that can exclusively and noninvasively detect apoptotic tissues in vivo.…”